CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 7, 2013, Pages 877-884

  Romme Christensen, Jeppe ^a   Börnsen, Lars ^a   Khademi, Mohsen ^b   Olsson, Tomas ^b   Jensen, Poul Erik ^a   Sørensen, Per Soelberg ^a   Sellebjerg, Finn ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

axonal damage; cerebrospinal fluid; demyelination; ELISA; inflammation; Multiple sclerosis; oxidative stress

Indexed keywords

CXCL13 CHEMOKINE; DIRUCOTIDE; GELATINASE B; OSTEOPONTIN;

ADULT; ARTICLE; AXONAL INJURY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; DEMYELINATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS;

EID: 84878347050     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512466929     Document Type: Article

References (36)

1. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000 ; 343: 1430-1438
2. Scalfari A, Neuhaus A, Daumer M, et al. Age and disability accumulation in multiple sclerosis. Neurology. 2011 ; 77: 1246-1252
3. Bradl M, Lassmann H.. Progressive multiple sclerosis. Semin Immunopathol. 2009 ; 31: 455-465
4. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005 ; 128 (Pt 11). 2705-2712
5. Kutzelnigg A, Faber-Rod JC, Bauer J, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 2007 ; 17: 38-44
6. Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. 2000 ; 157: 267-276
7. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009 ; 132 (Pt 5). 1175-1189
8. Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011 ; 134 (Pt 9). 2755-2771
9. Compston A, Coles A.. Multiple sclerosis. Lancet. 2008 ; 372: 1502-1517
10. Lassmann H, van Horssen J.. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett. 2011 ; 585: 3715-3723
11. Leary SM, Thompson AJ.. Primary progressive multiple sclerosis: Current and future treatment options. CNS Drugs. 19: 369-376
12. Rovaris M, Confavreux C, Furlan R, et al. Secondary progressive multiple sclerosis: Current knowledge and future challenges. Lancet Neurol. 2006 ; 5: 343-354
13. Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009 ; 73: 2003-2010
14. Bornsen L, Khademi M, Olsson T, et al. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler. 2011 ; 17: 32-42
15. Malmestrom C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003 ; 61: 1720-1725
16. Petzold A, Eikelenboom MJ, Keir G, et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: Three year follow up study. J Neurol Neurosurg Psychiatry. 2005 ; 76: 206-211
17. Lamers KJ, Uitdehaag BM, Hommes OR, et al. The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 1988 ; 51: 1334-1337
18. Danilov AI, Andersson M, Bavand N, et al. Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. J Neuroimmunol. 2003 ; 136: 112-118
19. Rejdak K, Eikelenboom MJ, Petzold A, et al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology. 2004 ; 63: 1439-1445
20. Freedman MS, Bar-Or A, Oger J, et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology. 2011 ; 77: 1551-1560
21. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121-127
22. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001 ; 294: 1731-1735
23. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002 ; 8: 500-508
24. Hur EM, Youssef S, Haws ME, et al. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol. 2007 ; 8: 74-83
25. Braitch M, Nunan R, Niepel G, et al. Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Arch Neurol. 2008 ; 65: 633-635
26. Khademi M, Bornsen L, Rafatnia F, et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: Prospects for treatment-sensitive biomarkers. Eur J Neurol. 2009 ; 16: 528-536
27. Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006 ; 129 (Pt 1). 200-211
28. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004 ; 14: 164-174
29. Owens T, Bechmann I, Engelhardt B.. Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol. 2008 ; 67: 1113-1121
30. Leppert D, Ford J, Stabler G, et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain. 1998 ; 121 (Pt 12). 2327-2334
31. Sinclair C, Mirakhur M, Kirk J, et al. Up-regulation of osteopontin and alphaBeta-crystallin in the normal-appearing white matter of multiple sclerosis: An immunohistochemical study utilizing tissue microarrays. Neuropathol Appl Neurobiol. 2005 ; 31: 292-303
32. Lindberg RL, De Groot CJ, Montagne L, et al. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain. 2001 ; 124 (Pt 9). 1743-1753
33. Sellebjerg F, Christiansen M, Nielsen PM, et al. Cerebrospinal fluid measures of disease activity in patients with multiple sclerosis. Mult Scler. 1998 ; 4: 475-479
34. Sellebjerg F, Christiansen M, Jensen J, et al. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol. 2000 ; 7: 281-289
35. Sellebjerg F, Jensen CV, Larsson HB, et al. Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis. Mult Scler. 2003 ; 9: 102-107
36. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011 ; 69: 83-89